The milestone will be paid pursuant to an acquisition agreement for Trisenox
previously entered into with Teva.
According to CTI BioPharma Corp, the expected milestone payment is related to the US Food and Drug Administration's approval of TRISENOX
(arsenic trioxide) for first line treatment of acute promyelocytic leukemia.
was reportedly acquired from CTI BioPharma by Cephalon Inc, which was subsequently acquired by Teva.
In a previous agreement, TRISENOX
was acquired from CTI BioPharma by Cephalon, which was subsequently acquired by Teva.
is indicated for the induction of remission and consolidation in patients with APL who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose APL is characterized by the presence of the t(15;17) translocation of PML/RAR-alpha gene expression.
is currently indicated for second line treatment of patients, who have not responded to treatment with retinoids and chemotherapy, or when their disease has returned after this type of treatment.
Biopharmaceutical company CTI BioPharma (NASDAQ:CTIC)(MTA:CTIC) reported on Thursday the receipt of USD15m milestone payment from Teva Pharmaceutical Industries related to the achievement of sales milestones for TRISENOX
Establishing a commercial presence in Europe is part of Cell Therapeutics' strategic plan to expand the clinical development and sales of TRISENOX
," stated James A.
Biopharmaceutical company Cell Therapeutics Inc (NASDAQ:CTIC)(MTA:CTIC) reported on Monday the receipt of a USD5m milestone payment related to the achievement of a sales milestone for TRISENOX
TEVA ) associated to the attainment of a sales milestone for TRISENOX
M2 EQUITYBITES-December 2, 2013-Cell Therapeutics Inc wins USD5m milestone payment for TRISENOX
According to Hoover's, CTIC's flagship product, Trisenox
, has been approved by the FDA to combat a certain type of leukemia.